Risedronate sodium is a nitrogen-containing bisphosphonate that inhibits osteoclast-mediated bone resorption and modulates bone metabolism.
Risedronate sodium is used for the treatment of postmenopausal osteoporosis to reduce the risk of vertebral fractures, treatment of established postmenopausal osteoporosis to reduce the risk of hip fractures, treatment of osteoporosis in men at high risk of fractures, and treatment of Paget’s disease. It is marketed as Actonel (tablet) and Atelvia (delayed-release tablet).
